Bleeding control during rhinoplasty. Haemorrhage and haematoma complicating a procedure, not elsewhere classified
Conditions
Interventions
Intervention 1: Intervention group: Patients in this group will receive tranexamic acid (TXA) at a dose of 10 mg/kg as a subcutaneous injection at the surgical site after induction of general anesthes
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: .Primary rhinoplasty surgery candidate Patients without underlying coagulation or significant cardiovascular disease No current use of anticoagulant or antiplatelet medications Patients with ASA I or ASA II Age between 18 and 50 years
Exclusion criteria
Exclusion criteria: .People with a history of severe allergic reaction to tranexamic acid Pregnancy or breastfeeding Any active infection or inflammatory disease in the nasal area
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Amount of bleeding during rhinoplasty surgery. Timepoint: At the end of surgery and closing the nose. Method of measurement: Using the volume of blood in the suction device after subtracting the washing fluid, the difference in weight of the used gases and the dry gases, the Boezaart scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Systolic Blood pressure. Timepoint: At the beginning of the surgery and then every half hour until the end of the surgery. Method of measurement: Non-invasive Blood pressure monitor.;Diastolic Blood Pressure. Timepoint: At the beginning of the surgery and then every half hour until the end of the surgery. Method of measurement: Non-invasive Blood pressure monitor.;Heart rate. Timepoint: At the beginning of the surgery and then every half hour until the end of the surgery. Method of measurement: Vital signs monitor and ECG leads. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Behzad Nazemroaya
Esfahan University of Medical Sciences
Outcome results
None listed